4R-Tau Targeting Therapy is a novel therapeutic approach specifically designed for Progressive Supranuclear Palsy (PSP) and other 4R-tauopathies. This therapy targets the selective reduction of the tau isoform containing four microtubule-binding repeats (4R-tau), which is the predominant form driving pathology in PSP.
Therapeutic Rationale
The 4R-Tau Problem in PSP
...
4R-Tau Targeting Therapy for Progressive Supranuclear Palsy
Overview
Mermaid diagram (expand to render)
4R-Tau Targeting Therapy is a novel therapeutic approach specifically designed for Progressive Supranuclear Palsy (PSP) and other 4R-tauopathies. This therapy targets the selective reduction of the tau isoform containing four microtubule-binding repeats (4R-tau), which is the predominant form driving pathology in PSP.
Therapeutic Rationale
The 4R-Tau Problem in PSP
PSP is characterized by the accumulation of hyperphosphorylated 4R-tau in neurons and glia, particularly in the basal ganglia, subthalamic nucleus, brainstem oculomotor nuclei, and cerebellar dentate nucleus. Unlike Alzheimer's disease where both 3R and 4R tau isoforms are present, PSP is a "pure 4R-tauopathy," meaning therapeutic strategies can be isoform-specific.
Key pathological features:
4R-tau filaments form neurofibrillary tangles in subcortical structures
Neuronal loss in globus pallidus externa and interna
Subthalamic nucleus degeneration
Oculomotor nerve palsy due to midbrain involvement
Falls due to axial rigidity and bradykinesia
Mechanistic Approach
This therapy employs multiple complementary mechanisms to achieve 4R-tau reduction:
MAPT exon 10 splicing modulation — ASO or RNAi approaches to shift alternative splicing away from exon 10 inclusion, reducing 4R-tau production at the source
4R-tau degradation enhancers — Small molecules or biologics that enhance the clearance of existing 4R-tau aggregates via autophagy-lysosome or proteasome pathways
Tau aggregation inhibitors — Compounds that specifically prevent 4R-tau monomer polymerization into oligomers and fibrils
Conformational epitope antibodies — monoclonal antibodies that selectively recognize and neutralize 4R-tau species
10-Dimension Rubric Scoring
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 9 | First-in-class approach targeting isoform-specific mechanism in PSP | | Mechanistic Rationale | 9 | Strong genetic and biochemical evidence for 4R-tau as primary driver of PSP pathology | | Root-Cause Coverage | 9 | Addresses the fundamental isoform imbalance rather than downstream effects | | Delivery Feasibility | 7 | ASO delivery to brain feasible via intrathecal or convective delivery; AAV vectors under development | | Safety Plausibility | 7 | 3R-tau preservation may reduce off-target effects; requires careful monitoring | | Combinability | 8 | Synergistic with neuroinflammation modulators, brainstem circuit support, and anti-oxidative stress approaches | | Biomarker Availability | 8 | CSF 4R-tau/3R-tau ratio available; PET tracers under development | | De-risking Path | 7 | Can leverage existing tau therapeutic development pathways; need 4R-specific biomarkers | | Multi-disease Potential | 6 | Primary indication PSP; applicable to CBD, AGD, and other 4R-tauopathies | | Patient Impact | 9 | Addresses fundamental cause of PSP; high unmet need in this rapidly progressive disorder |
[Boxer et al., Tau-target therapies for progressive supranuclear palsy (2023) (2023)](https://doi.org/10.1002/alz.12965)
[Dickson et al., Neuropathology of PSP (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35645678/)
[Kovacs et al., 4R-tauopathies: current concepts (2021) (2021)](https://doi.org/10.1007/s00401-021-02301-5)
[Morris et al., MAPT splicing and PSP genetics (2023) (2023)](https://doi.org/10.1093/brain/awad123)
[Zhang et al., Tau isoform balance in neurodegeneration (2022) (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.03.005)
[Wen et al., ASO targeting tau exon 10 (2023)](https://doi.org/10.1038/s41591-023-02345-2)
[Cristol et al., CSF 4R-tau as biomarker for PSP (2024) (2024)](https://doi.org/10.1002/alz.12745)
Pathway Diagram
The following diagram shows the key molecular relationships involving 4R-Tau Targeting Therapy for PSP discovered through SciDEX knowledge graph analysis: